Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Thanks, everybody, for joining us. I'm Terence Flynn, the biopharma analyst here at Goldman. This morning we're very pleased to welcome Regeneron.
And joining us from the company is Jay Markowitz, Senior Vice President of Portfolio Management. Thanks, Jay, for joining us. Really appreciate the time this morning.
My pleasure.
Questions & Answers
Maybe just to kick it off at a high level, I think the one thing is, the company has been front and center in so many of the discussions on drug pricing. EYLEA, you notably haven't taken any price increases since launch. You guys worked with ICER with respect to PRALUENT pricing. DUPI, you guys had engaged payers very early, ahead of the launch.
Maybe just as we think about the forward here, what differentiates your approach, I guess?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |